New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
14:09 EDTTEVA, VRX, RDY, PRGOSun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Indian drugmaker Sun Pharmaceutical will buy another Indian pharmaceutical company, Ranbaxy, for $3.2B, the companies said earlier today. Ranbaxy specializes in developing generic drugs. WHAT'S NEW: Sun will buy Ranbaxy in an all-stock transaction via which Ranbaxy shareholders will receive 0.8 shares of Sun Pharma for each share of Ranbaxy. The transaction price represents a premium of 18% to Ranbaxy’s 30-day volume-weighted average share price, the companies stated The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India, the companies noted. WHAT'S NOTABLE: It came to light late last week that another generic drug maker, Mylan (MYL), attempted to buy a Swedish rival, Meda. Meda's board of directors confirmed on Friday that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." OTHERS TO WATCH: Other generic drug makers include Teva (TEVA), Valeant (VRX), Dr. Reddy’s (RDY), and Perrigo (PRGO). PRICE ACTION: In mid-afternoon trading, Mylan fell 3% and Valeant slid over 4%, while Teva, Dr. Reddy's and Perrigo all retreated about 2%.
News For TEVA;VRX;RDY;PRGO From The Last 14 Days
Check below for free stories on TEVA;VRX;RDY;PRGO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 15, 2014
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
July 14, 2014
16:30 EDTPRGOOn The Fly: Closing Wrap
Subscribe for More Information
12:47 EDTVRXAllergan slides question Valeant growth, disclosures, says BMO Capital
Subscribe for More Information
10:49 EDTPRGOPerrigo hires bank, seeks merger with large peer, Globes says
Subscribe for More Information
10:48 EDTPRGOPerrigo calls active on circulation of Globes report
Perrigo July 145, 150 and 155 calls are active on total call volume of 1500 contracts (300 puts) following the circulation of Globes report. July call option implied volatility 50, August is at 40, November is at 31; compared to its 26-week average of 29 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:38 EDTPRGOPerrigo move higher attributed to circulation of Globes report
Subscribe for More Information
08:13 EDTVRXAllergan reiterates belief that Valeant model unsustainable in new presentation
Subscribe for More Information
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
08:02 EDTVRXValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
July 11, 2014
16:48 EDTVRXAllergan comments on Pershing Square’s definitive proxy solicitation
Allergan (AGN) provided the following comment in response to the definitive proxy solicitation filed by Pershing Square Capital Management in connection with Pershing Square’s request to call a Special Meeting of Stockholders. At the Special Meeting, if called, Allergan stockholders would be asked to remove a majority of the company’s existing directors in connection with Valeant Pharmaceuticals' (VRX) unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant common shares with the implied value set forth in the exchange offer. Under the current Board’s leadership, which includes individuals with significantly more industry experience than Pershing Square’s recommended nominees, Allergan continues to execute on its plan to drive near- and long-term organic growth, enhance its growth prospects and continue generating significant value for all of Allergan’s stockholders. We believe Pershing Square’s attempt to replace a majority of the Allergan Board is a further effort to support Valeant in its bid to acquire Allergan at a grossly inadequate price that substantially undervalues the company and creates significant risks and uncertainties for Allergan stockholders. Valeant has repeatedly failed to address the serious concerns raised by Allergan and important members of the investment community about Valeant’s anemic organic growth driven by unsustainable price increases, among other fundamental business model issues. Allergan has a track record of consistently acting in the best interests of its stockholders and the Board remains confident in the company’s ability to create significantly more value than Valeant’s proposal.
10:00 EDTPRGOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:15 EDTPRGOPerrigo downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
July 10, 2014
10:46 EDTPRGOPerrigo management to meet with Guggenheim
Meeting to be held in New York on July 16 hosted by Guggenheim.
09:31 EDTVRXNestle acquires rights to aesthetic dermatology products in the U.S. and Canada
Subscribe for More Information
09:31 EDTVRXValeant completes filler, toxin asset sale to Galderma
Subscribe for More Information
July 9, 2014
18:31 EDTVRXShareholders urge Allergan to make large acquisition, FT reports
Subscribe for More Information
18:21 EDTVRXAllergan CEO seeks sizeable acquisitions, WSJ reports
Subscribe for More Information
07:15 EDTTEVATeva, others fined $583.4M by EU regulators, Reuters says
Subscribe for More Information
06:49 EDTTEVAGeneric drug prices have risen significantly, NY Times says
Subscribe for More Information
06:19 EDTVRXAllergan plans broad restructuring plan, Bloomberg says
Allergan (AGN), the pharmaceutical maker that is being chased by Valeant (VRX) and Bill Ackman’s hedge fund, will shelve unpromising pipeline medicines and revamp management incentives, according to Bloomberg, citing two people with knowledge of the matter. The sources said that the restructuring plan, which is set to be explained during Allergan's upcoming earnings announcement, will also detail companywide cost reductions including some legacy expenses. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use